Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years. After detailed deliberation, the committee recommended for conduct of proposed phase II/III clinical trial of whole virion inactivated coronavirus vaccine in the 2 to 18 years age group subject to the condition that the firm should submit the interim safety data of phase II clinical trial along with DSMB recommen
Source:
Highlights
According to the scientist, COVID-19 cases in the second wave also won t come down in as steady a fashion as they did after the first wave
In his view, the actual mortality data for India is completely wrong, not because of some evil design of someone or a group of people or the state or whatever
New Delhi: India s second COVID-19 wave seems to have flattened but the climb down will be a more prolonged, long-drawn-out process than the first and will possibly run till July, says eminent virologist Shahid Jameel.
Though the new variants of the virus may partly be responsible for the explosion in the number of cases, there is no indication the mutant versions are more lethal, added the director of the Trivedi School of Biosciences, Ashoka University, amid mounting worries about what is fuelling the second wave in India.
: Wednesday, May 12, 2021, 8:33 AM IST
COVID-19 Vaccine in India: Bharat Biotech s Covaxin recommended for Phase II/III trials on 2 to 18 year-olds
(Photo by AFP)
While India expanded it s COVID-19 vaccination drive to include all adults at the beginning of May, children have remained excluded from both trials and the inoculation drive for the most part. That however is now set to change, with an expert panel recommending Bharat Biotech s Covaxin for phase II/III clinical trial on those aged between two to 18 years.
As per reports, the trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxi
India s second COVID-19 wave seems to have flattened but the climb down will be a more prolonged, long drawn-out process than the first and will possibly run till July, eminent virologist Shahid Jameel said here on Tuesday. Though the new variants of the virus may partly be responsible for the explosion in the number of cases, there is no indication the mutant versions are more lethal, added the director of the Trivedi School of Biosciences, Ashoka University, amid mounting worries about what is fuelling the second wave in India. Addressing an online event organised by the Indian Express, Jameel noted that it is a little too early to say if the Covid wave has peaked.
Representative image
RANCHI: As many as 29,206 people, who are aged between 18-44 years and had registered themselves for vaccination till May 10 through CoWin and Aarogya Setu in the third phase of the drive due to begin in Jharkhand on May 14.
Since the online registrations for the third phase began on April 28, the most number of applicants have been from Ranchi (9,780) followed by Bokaro (8,550) and East Singhbhum (4,226). The least number were in Simdega (19), Latehar (20) and Khunti (21).
The poor registration figures in rural districts are a concern for health department officials. “The registrations were low because the vaccines did not arrive before May 1 and the drive was postponed till the availability of vaccines. We are hopeful that the turnout will increase once the drive is underway,” a senior official said on anonymity.